A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Inclusion Criteria

• Inclusion Criteria: Among other criteria, patients must meet all of the following conditions to be eligible for the study: - Unresectable, histologically-confirmed advanced (Stage III or Stage IV) melanoma - Disease progression during or after the last anticancer therapy received. For Cohort 3, progression must have occurred during the PD-1 targeted CPI (checkpoint inhibitor) treatment and the investigator has deemed it appropriate to continue treatment with the PD-1 targeted CPI beyond confirmed disease progression - No more than one prior chemotherapy-containing regimen for advanced disease. - Prior treatments received must include at least one CPI inhibitor (e.g., anti-CTLA-4, PD-1-, PD-L1-targeted immunotherapy) and for patients with a BRAF mutation at least one BRAF- or MEK-targeted therapy, unless patients are not candidates for, or refused, these therapies. For cohort 3, prior treatment received must include a PD-1 targeted CPI administered during the most recent disease progression and for patients with BRAF mutation at least one BRAF- or MEK-targeted therapy when appropriate - The study site will submit paraffin-embedded tumor tissue obtained from the patient for gpNMB analysis. Patients may require a biopsy if recent tumor tissue is not available. Patients in cohort 2 and 3 must submit a recently obtained biopsy of the skin fold for gpNMB analysis. Patients in Cohort 4 will submit a tumor tissue sample while on study. - Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 - Adequate bone marrow, liver and renal function. Exclusion Criteria: Among other criteria, patients who meet any of the following conditions are NOT eligible for the study: - Previously received glembatumumab vedotin (CR011-vcMMAE, CDX-011) or other MMAE-containing agents - Treatment with the following therapies before the planned start of study treatment: 1. BRAF or MEK inhibitors within 2 weeks 2. Monoclonal based therapies within 4 weeks except for the PD-1 targeted checkpoint inhibitor in cohort 3 3. Immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within 2 weeks 4. Chemotherapy within 21 days or at least 5 half-lives (whichever is longer) 5. Investigational therapy within 2 weeks (or at least 5 half-lives, whichever is longer) - Patients with ocular melanoma - Neuropathy that is moderate (Grade 2) or worse. - Cancer that has spread to the brain or spine will be discussed with the study sponsor and may exclude patients from the trial. - History of another cancer except: 1. Patients with adequately treated and cured non-melanoma skin cancer or in situ cancer 2. Patients with any other cancer from which the patient has been disease-free for ≥ 3 years - Significant cardiovascular disease - Previously received varlilumab or any other anti-CD27 mAb (Cohort 2 only) - Active systemic infection requiring treatment - Treatment with immunosuppressive medications within 4 weeks or corticosteroids within two weeks - Patients with interstitial lung disease (Cohort 3 only) - Patients with active diverticulitis (Cohort 3 only) - Any non-study vaccination within 4 weeks, or influenza vaccine within 2 weeks, prior to CDX-301 dosing (Cohort 4 only)